NA
MRVI icon

NewEdge Advisors’s Maravai LifeSciences MRVI Stock Holding History

NewEdge Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$207K Buy
+33,193
New +$143K ﹤0.01% 2749
2026
Q1 		– Sell
-46
Closed -$150 – 4293
2025
Q4 		$150 Hold
46
– – ﹤0.01% 4147
2025
Q3 		$132 Hold
46
– – ﹤0.01% 4023
2025
Q2 		$111 Hold
46
– – ﹤0.01% 3901
2025
Q1 		$102 Sell
46
-11
-19% -$43 ﹤0.01% 3827
2024
Q4 		$311 Hold
57
– – ﹤0.01% 3715
2024
Q3 		$473 Hold
57
– – ﹤0.01% 3608
2024
Q2 		$408 Sell
57
-362
-86% -$3.13K ﹤0.01% 3587
2024
Q1 		$3.63K Sell
419
-189
-31% -$1.28K ﹤0.01% 3245
2023
Q4 		$3.98K Buy
608
+562
+1,222% +$3.63K ﹤0.01% 3184
2023
Q3 		$460 Sell
46
-117
-72% -$1.28K ﹤0.01% 3265
2023
Q2 		$2.03K Buy
163
+117
+254% +$1.58K ﹤0.01% 3092
2023
Q1 		$644 Sell
46
-37
-45% -$531 ﹤0.01% 3216
2022
Q4 		$530 Buy
+83
New +$1.31K ﹤0.01% 3157

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

NewEdge Advisors's MRVI Position: Q2 2026 in Review

NewEdge Advisors opened a new position in Maravai LifeSciences (MRVI) in Q2 2026: 33,193 shares worth $207K. The stake represents ﹤0.01% of the portfolio and ranks #2749 among its holdings. This is a return to the name: NewEdge Advisors previously reported a position in MRVI as recently as Q4 2025.

NewEdge Advisors first reported a position in MRVI in Q4 2022 and has held it in 14 quarters since. 177 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • NewEdge Advisors held 33,193 shares of Maravai LifeSciences worth $207K as of Q2 2026.
  • Maravai LifeSciences was a new NewEdge Advisors position in Q2 2026.
  • Maravai LifeSciences made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2749 holding.
  • NewEdge Advisors first reported a position in Maravai LifeSciences in Q4 2022 and has held it in 14 quarters since.
  • 177 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.